Platinum-sensitivity in metastatic colorectal cancer: Towards a definition

European Journal of Cancer

Volumn 49, Issue 18, 2013, Pages 3813-3820

  Chibaudel, Benoist ^a,b,d   Tournigand, Christophe ^a,b,c   Bonnetain, Franck ^e   Maindrault Goebel, Frédérique ^a,c   Lledo, Gérard ^f   André, Thierry ^a,b,c   Larsen, Annette K ^b,c   Bengrine Lefevre, Leila ^a   Louvet, Christophe ^b,c,g   De Gramont, Aimery ^a,b,c  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d GERCOR   (France)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

^f Centre Orthopédique Santy Hôpital Privé Jean Mermoz   (France)

^g INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

Chemotherapy; Colorectal cancer; FOLFOX; Oxaliplatin; Stop and go

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; OXALIPLATIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

CHEMOTHERAPY; COLORECTAL CANCER; FOLFOX; OXALIPLATIN; STOP-AND-GO;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; REMISSION INDUCTION; RETREATMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888012248     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.07.150     Document Type: Article

References (21)

1. J. Cassidy, S. Clarke, and E. Diaz-Rubio Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 2008 2006 2012
2. S. Giacchetti, B. Perpoint, and R. Zidani Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer J Clin Oncol 18 2000 136 147
3. C. Tournigand, A. Cervantes, and A. Figer OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer - a GERCOR study J Clin Oncol 24 2006 394 400
4. F. Maindrault-Goebel, C. Tournigand, and T. Andre Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer Ann Oncol 15 2004 1210 1214
5. A. de Gramont, M. Buyse, and J.C. Abrahantes Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer J Clin Oncol 25 2007 3224 3229
6. M. Markman, and W. Hoskins Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population J Clin Oncol 10 1992 513 514
7. B. Chibaudel, F. Maindrault-Goebel, and G. Lledo Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study J Clin Oncol 27 2009 5727 5733
8. N. Perez-Staub, B. Chibaudel, and A. Figer Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer? A GERCOR study J Clin Oncol 26 Suppl. 2008 4037
9. B.J. Giantonio, P.J. Catalano, and N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544
10. P.R. Rosenbaum, and D.B. Rubin The central role of the propensity score in observational studies for causal effects Biometrica 70 1983 41 55
11. P.C. Austin The performance of different propensity-score methods for estimating relative risks J Clin Epidemiol 61 2008 537 545
12. R.B. D'Agostino Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 1998 2265 2281
13. R.A. Adams, A.M. Meade, and M.T. Seymour Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet Oncol 12 2011 642 653
14. A. Grothey, L.L. Hart, and K.M. Rowland Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial J Clin Oncol 26 Suppl. 2008 180s [abstr 4010]
15. D.M. Gershenson, J.J. Kavanagh, and L.J. Copeland Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy Obstet Gynecol 73 1989 798 802
16. M.E. Gore, I. Fryatt, and E. Wiltshaw Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol Oncol 36 1990 207 211
17. R.I. Fisher, V.T. DeVita, and S.P. Hubbard Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse Ann Intern Med 90 1979 761 763
18. G. Batist, D.C. Ihde, and A. Zabell Small-cell carcinoma of lung: reinduction therapy after late relapse Ann Intern Med 98 1983 472 474
19. C. Tournigand, B. Samson, and W. Scheithauer Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): efficacy and safety results of the International GERCOR DREAM phase III trial J Clin Oncol 30 Suppl. 2012 [abstr LBA3500^]
20. Punt C. Maintenance treatment versus observation after induction in advanced colorectal carcinoma (CAIRO3). < http://clinicaltrials.gov/ct2/show/ NCT00442637 > [accessed 06.03.13].
21. Hegewisch-Becker S. Optimal maintenance therapy with bevacizumab after induction in metastatic colorectal cancer (CRC). < http://clinicaltrials.gov/ ct2/show/NCT00973609 > [accessed 06.03.13].